DESTINY-Breast03

NCT03529110 📎

Regimen

Experimental
Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg IV every 3 weeks.
Control
T-DM1 3.6 mg/kg IV every 3 weeks.

Population

HER2-positive metastatic or unresectable breast cancer previously treated with trastuzumab and taxane.

Key finding

DESTINY-Breast03 replaced T-DM1 with T-DXd as 2L HER2+ MBC standard (NCCN category 1). Largest magnitude PFS benefit in the subtype's history (HR 0.33); matched by OS benefit. Defines current 2L standard.

Source: PMID 35320644

Timeline

  • Publication: 2022 Mar 24

Guideline citations

  • NCCN BREAST